| Bid | 15.13 |
| Market Cap | 2.09B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.07 |
| PE Ratio (ttm) | 35.37 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 45 |
| Volume | 152,036 |
| Avg. Volume (20D) | 363,385 |
| Open | 37.70 |
| Previous Close | 37.57 |
| Day's Range | 37.44 - 37.91 |
| 52-Week Range | 25.53 - 39.37 |
| Beta | undefined |
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy tr...
Analyst Forecast
According to 1 analyst ratings, the average rating for SUPN stock is "Hold." The 12-month stock price forecast is $36, which is a decrease of -4.89% from the latest price.
Next Earnings Release
Analysts project revenue of $154.25M, reflecting a -6.12% YoY shrinking and earnings per share of 0.5, making a 28.21% increase YoY.
2 months ago · seekingalpha.com
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering GrowthSupernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue gro...
2 months ago · seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call TranscriptSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Exe...
